Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP640 | DOI: 10.1530/endoabs.49.EP640

Service of Endocrinology Diabetes and metabolic diseases, Cadi Ayad University, CHU Mohamed VI., Marrakech, Morocco.


Contexte: Acromegaly is a rare disease, usually caused by hypersecretion of growth hormone (GH) by a pituitary adenoma and very rarely by ectopic secretion of GHRH. It remains a serious disease reduces life expectancy because of its cardiovascular and metabolic impact.

Objective: The objective of this study is to report the glycemic profile in patients followed for acromegaly in the endocrinologic center of CHU Med VI of Marrakech.

Patient – Intervention: We performed a retrospective study over a period of 2 years. Fifteen cases were identified.

Intervention: In terms of methodology, we studied: a family history of diabetes, hypertension and dyslipidemia; Girth, body mass index (BMI), hypertension, diabetes mellitus or impaired glucose tolerance and dyslipidemia in these patients.

Main outcome measure: Glucose intolerance and diabetes with insulin resistance are commonly encountered complications acromegaly. Some studies have shown a direct correlation between the rate of GH and the degree of glucose intolerance. The hyperinsulinemia and insulin resistance may play an important role in the cardiovascular risk of these patients. The role of insulin resistance, but also of pancreatic β dysfunction has been invoked in the pathogenesis of carbohydrate metabolism disturbances secondary to chronic excess GH.

Result: The average age was 43 years (20–63) with a sex ratio (M/F) =0.33. The duration of the disease at diagnosis was on average 7 years (3–14). Family history were 13.3% diabetes mellitus and heart disease. Pathological BMI was objectified in 52% of cases; 46.6% of these patients had pre-diabetes, 40% diabetic (a total of 84.6% of carbohydrate anomalies) and 46.7% had dyslipidemia. Moreover 26.6% of our patients where hypertensive.

Conclusion: Approximately 84.6% in our series of cases had carbohydrate abnormalities. Diagnostic and therapeutic delay can worsen or even cause the patient’s death. After surgical recovery, the evolution of diabetes and/or glucose intolerance is usually favorable.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts